智通财经APP讯，戴维医疗(300314.SZ)发布公告，公司于近日取得1项由国家药品监督管理局颁发的《受理通知书》，受理号为：CQZ2501333，产品名称：呼吸机。
呼吸机是一种关键的生命支持类医疗设备，主要用于辅助或替代患者自主呼吸功能。其核心作用是通过向患者肺部输送精确配比的空氧混合气体，协助完成气体交换过程(即吸入氧气和排出二氧化碳)，从而维持生命体征稳定或促进患者康复。本次申报产品为电动电控型呼吸机，具备多种临床适用的通气模式，包括有创通气、无创通气以及高流量氧疗模式，适用于患者治疗的各个阶段，从无自主呼吸的紧急抢救直至逐步撤机的康复过程。该产品还集成了脉搏血氧饱和度监测与呼气末二氧化碳监测功能，能够实时、连续地评估患者的氧合与通气状态，通过这些关键生理参数的动态监测，临床医生可以更精准地调整呼吸机设置。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.